Andreas Hougaard Laustsen-Kiel, PhD profile page

Professor Andreas Hougaard Laustsen-Kiel heads the Section for Biologics Engineering at the Department of Biotechnology and Biomedicine at the Technical University of Denmark (DTU) and is a leading expert on antibody technologies, where he specializes in the discovery of antibodies against toxins from venomous animals and bacteria. In particular, he was the first to discover human monoclonal antibodies against snake toxins and to formulate many of the principles behind the concept of recombinant antivenoms. He is also a co-founder of the biotech companies and spinouts, Biosyntia, VenomAb, Antag Therapeutics, Chromologics, VenomAid Diagnostics, Agrobiomics, Combotope Therapeutics, Y-king Biologics, and Bactolife, which employ approximately 120 FTEs combined. He holds a PhD from the University of Copenhagen and an MSc Eng from DTU. He has published 115+ peer-reviewed scientific articles, is cited 5500 times (Google Scholar), is a co-inventor of 16 patent families, has (co-)raised USD 280 million for research and entrepreneurship, has supervised 8 graduated PhD students, and is currently supervising 6 more. He is recognized as Denmark’s Coolest Engineer (Engineer The Future), was listed on Forbes 30 under 30 in 2017, and was a Top 35 Innovator under 35 by MIT Technology Review in 2017. In 2023, 2024, and 2025, Andreas was the first and only individual to be awarded with the three most prestigious research awards for younger scientists in Denmark, namely the Silver Medal for Excellent Basic Research by the Royal Danish Academy of Sciences and Letters (2023), the Lundbeck Young Investigator Prize by the Lundbeck Foundation (2024), and the Elite Research Prize by the Danish Ministry of Higher Education and Science (2025).